The safety of NKG2D(z) CAR-T cells has also been demonstrated in clinical trials of myelodysplastic syndromes/acute myeloid leukemia and relapsed/refractory multiple myeloma (15, 16). Here, KLRK1 is linked to plasma cell myeloma.